The current diagnostic tools in a pathologist’s arsenal sometimes cannot provide a clear distinction between primary mediastinal large B-cell lymphoma (one of the few lymphomas more common in younger women) and diffuse large B-cell lymphoma, the most common type of non-Hodgkin’s lymphoma overall. This may occasionally give rise to diagnostic inaccuracy in routine practice and could leave physicians guessing as to the best course of therapy for their patients.
On April 18, a team of researchers led by Lisa Rimsza, M.D., a pathologist and director of the Mayo Clinic Molecular Diagnostics – Arizona Laboratory launched a new genetic test, the Lymph3Cx, which distinguishes between the two types of lymphoma. The establishment of the test and their study results were published in the journal Blood.
Having a test like this available in a clinical laboratory setting can help physicians, determine the correct classification of lymphoma to improve therapeutic decision-making for patient care. The test can also be used as a tool to support clinical trials. Read the rest of the article on Discovery's Edge.
Liked by Lisa Lucier, Connect Moderator